Evidence map›Paper›PMID 42168605›Full record

ArticleCommunications chemistry2026

Direct amidinium-phosphate interactions guide AT-selective DNA binding by a potent antileishmanial drug.

Jorge Jonathan Nué-Martinez, Cristina Ugedo, Laura Lagartera, José Cumella, Christophe Dardonville, Miguel Garavís

Abstract read
In one paragraph

Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jorge Jonathan Nué-Martinez *Instituto de Química Médica (IQM-CSIC) C/ Juan de la Cierva 3, Madrid, Spain.ORCID http://orcid.org/0000-0001-6483-6892
Cristina Ugedo *Instituto de Química Física 'Blas Cabrera' (IQF-CSIC) C/ Serrano 119, Madrid, Spain.
Laura LagarteraInstituto de Química Médica (IQM-CSIC) C/ Juan de la Cierva 3, Madrid, Spain.
José CumellaInstituto de Química Médica (IQM-CSIC) C/ Juan de la Cierva 3, Madrid, Spain.
Christophe DardonvilleInstituto de Química Médica (IQM-CSIC) C/ Juan de la Cierva 3, Madrid, Spain. dardonville@iqm.csic.es.ORCID http://orcid.org/0000-0001-5395-1932
Miguel GaravísInstituto de Química Física 'Blas Cabrera' (IQF-CSIC) C/ Serrano 119, Madrid, Spain. mgaravis@iqf.csic.es.ORCID http://orcid.org/0000-0003-1889-1713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neglected tropical diseases caused by kinetoplastid parasites remain a major global health challenge, with current chemotherapies offering limited efficacy and safety. JNII40 is a promising bis(pyridine-2-carboxamidine) ligand with potent antiparasitic activity and selectivity in vivo against Leishmania parasites. The compound specifically targets AT-rich regions of DNA, predominant in the mitochondrion of these parasites. We used NMR spectroscopy to determine the high-resolution structure of a DNA duplex containing four consecutive AT repeats in complex with JNII40. The structure reveals that JNII40 binds deeply into the DNA minor groove through a network of direct and water-mediated hydrogen bonds, including direct interactions between amidine protons and DNA phosphate oxygens. These contacts, supported by extensive intermolecular NOEs, explain the high affinity and sequence selectivity toward AT-rich regions observed by calorimetry and NMR. Restrained molecular dynamics simulations highlight the critical role of two ordered water molecules that bridge the ligand and DNA, preserving the geometry of the complex. Ligand insertion induces a noticeable narrowing of the minor groove. Altogether, these findings provide a structural framework for the rational drug design of selective DNA-targeting molecules against kinetoplastid parasites such as Leishmania.

Identifiers

PMID42168605
PMCPMC13542123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.